These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11681769)

  • 1. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
    Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
    J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.
    Phillips KA; Pagano ME; Menard W
    Ann Clin Psychiatry; 2006; 18(4):251-7. PubMed ID: 17162625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
    Phillips KA
    Psychopharmacol Bull; 1996; 32(1):175-80. PubMed ID: 8927669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
    Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
    J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of body dysmorphic disorder.
    Phillips KA
    Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
    Phillips KA; Hollander E
    Body Image; 2008 Mar; 5(1):13-27. PubMed ID: 18325859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of escitalopram in body dysmorphic disorder.
    Phillips KA
    Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
    Phillips KA; Albertini RS; Rasmussen SA
    Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?
    Maina G; Albert U; Ziero S; Bogetto F
    Int Clin Psychopharmacol; 2003 Jan; 18(1):23-8. PubMed ID: 12490771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study of citalopram in body dysmorphic disorder.
    Phillips KA; Najjar F
    J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
    Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
    Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.